Monsenso A/S issues warrants to management and employees

24.3.2023 20:42:34 CET | Monsenso | Company Announcement

Company announcement no. 09-2023

Copenhagen, 2023.03.24

The Board of Directors of Monsenso A/S hereby announces the decision to issues warrants for employees and management, who are in a non-terminated position and who were employed on 1 January 2023.

Vesting period for the warrants is 36 months from 1 May 2023 to 30 April 2026, but only if the recipient is still employed by the company. Unexercised warrants expire on 31 August 2030. DKK 840,000 warrants have been granted, giving the right to subscribe for a nominal DKK 84,000 shares in the company.

The Board of Directors has set the exercise price at DKK 0.22 per warrant, which is less than the market price and in accordance with § 5.3 of the company's articles of association.

The warrant holder shall not pay any compensation for the granting of the warrants. The vested warrants can be exercised twice a year after publication of the company's annual and half-yearly report in an exercise window of pt. 2 weeks.

Monsenso's share capital amounts to a nominal value of DKK 3,050,211.10 divided into 30,502,111 shares of DKK 0.10.

Any inquiries regarding this notice should be directed to:

Monsenso

CEO
Thomas Lethenborg
Tel [phone]
E-mail: [e-mail] 

Chairman of the board
Peter Mørch Eriksen
Tel [phone]
E-mail: [e-mail]

Certified Adviser

Norden CEF A/S
John Norden

E-mail: [e-mail]

About Monsenso

Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

Attachments

• Download announcement as PDF.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases